Arcutis Biotherapeutics (Nasdaq:ARQT) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ARQT Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Arcutis Biotherapeutics, Inc. dermatolojik hastalıklar için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır.

Şirket hakkında

ARQT temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 87.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 69.32% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Arcutis Biotherapeutics, Inc. Rakipler

POINT Biopharma Global

NasdaqCM:PNT

US$1.3b

Entrada Therapeutics

NasdaqGM:TRDA

US$562.3m

Ardelyx

NasdaqGM:ARDX

US$1.6b

Verve Therapeutics

NasdaqGS:VERV

US$405.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Arcutis Biotherapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$10.23
52 Haftanın En Yüksek Seviyesi	US$13.17
52 Haftanın En Düşük Seviyesi	US$1.76
Beta	1.18
11 Aylık Değişim	-5.97%
3 Aylık Değişim	6.56%
1 Yıllık Değişim	127.33%
33 Yıllık Değişim	-56.69%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-53.07%

Son Haberler & Güncellemeler

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Hissedar Getirileri

	ARQT	US Biotechs	US Pazar
7D	12.4%	-0.2%	-0.4%
1Y	127.3%	22.1%	34.1%

Getiri vs. Endüstri: ARQT geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ARQT geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ARQT's price volatile compared to industry and market?
ARQT volatility
ARQT Average Weekly Movement	10.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ARQT son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ARQT 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2016	296	Frank Watanabe	www.arcutis.com

Bir biyofarmasötik şirketi olan Arcutis Biotherapeutics, Inc. dermatolojik hastalıklar için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Şirketin öncü ürün adayı, plak sedef hastalığı ve atopik dermatit tedavisi için Faz III klinik çalışmalarını tamamlamış olan topikal roflumilast krem ARQ-151'dir. Şirket ayrıca kafa derisi ve vücut sedef hastalığı ve seboreik dermatit tedavisi için topikal bir ZORYVE olan ARQ-154'ü; el egzaması ve vitiligo için seçici bir topikal janus kinaz tip 1 inhibitörü olan ARQ-252'yi; alopesi areata için topikal bir JAK1 inhibitörü olan ARQ-255'i ve orta ila şiddetli atopik dermatit tedavisi için bir CD200R füzyon proteini olan ARQ-234'ü geliştirmektedir.

Arcutis Biotherapeutics, Inc. Temel Bilgiler Özeti

Arcutis Biotherapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ARQT temel i̇stati̇sti̇kler
Piyasa değeri	US$1.12b
Kazançlar(TTM)	-US$198.76m
Gelir(TTM)	US$132.06m

9.1x

P/S Oranı

-6.0x

F/K Oranı

ARQT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ARQT gelir tablosu (TTM)
Gelir	US$132.06m
Gelir Maliyeti	US$10.15m
Brüt Kâr	US$121.91m
Diğer Giderler	US$320.68m
Kazançlar	-US$198.76m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.70
Brüt Marj	92.32%
Net Kâr Marjı	-150.51%
Borç/Özkaynak Oranı	109.3%

ARQT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ARQT Stoklara Genel Bakış

Ödüller

Risk Analizi

Arcutis Biotherapeutics, Inc. Rakipler

NasdaqCM:PNT

US$1.3b

NasdaqGM:TRDA

US$562.3m

NasdaqGM:ARDX

US$1.6b

NasdaqGS:VERV

US$405.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis Biotherapeutics, Inc. Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics, Inc. Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Consensus estimates of losses per share improve by 12%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis Biotherapeutics, Inc. Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics, Inc. Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Consensus estimates of losses per share improve by 12%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$131k worth of stock

Forecast to breakeven in 2026

Arcutis Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for Zoryve (Roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and over

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces the U.S. Food and Drug Administration's Approval of the Supplemental New Drug Application for ZORYVE (Roflumilast) Cream

Insufficient new directors

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Senior VP & Chief Medical Officer exercised options and sold US$201k worth of stock

Senior VP & Chief Medical Officer recently sold US$435k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Consensus revenue estimates increase by 36%

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology

President notifies of intention to sell stock

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023